Front Neuroendocrinol (2014) 35(3):34769
slow the administration Theoretical concerns Tumour promotion: animal studies at very high doses (far above clinical use) showed no pro-tumorigenic effects
Therefore, DEX-mediated increase in uric acid excretion is mainly due to the downregulation effect of URAT1 (Li et al., 2019)
Animal Toxicology Studies Animal toxicology studies tested doses from 0.0027 mg/lb to 9.1 mg/lb via intraperitoneal, intramuscular, intravenous, and oral routes for up to 6 weeks, finding: No acute toxic or lethal dose No gross or histologic toxicity in major organs No hepatotoxicity or nephrotoxicity Negative Ames test (no mutagenicity) Negative chromosomal aberration tests (no genotoxicity) No teratogenicity in rat pregnancy studies No local injection site irritation The LD1 (minimum lethal dose) could not be achieved despite aggressive testing
Always consult a qualified healthcare professional with questions about sleep apnea or any other medical condition
Weight loss during this period is often modest, perhaps 1 to 3 pounds, because the dose is below the threshold where all three receptors are fully engaged
